Advertisement
Singapore markets open in 5 hours 31 minutes
  • Straits Times Index

    3,304.00
    +2.22 (+0.07%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • Dow

    38,834.86
    +56.76 (+0.15%)
     
  • Nasdaq

    17,862.23
    +5.21 (+0.03%)
     
  • Bitcoin USD

    64,845.79
    +287.97 (+0.45%)
     
  • CMC Crypto 200

    1,383.19
    +45.44 (+3.40%)
     
  • FTSE 100

    8,205.11
    +13.82 (+0.17%)
     
  • Gold

    2,342.70
    -4.20 (-0.18%)
     
  • Crude Oil

    81.47
    -0.10 (-0.12%)
     
  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     
  • Nikkei

    38,570.76
    +88.65 (+0.23%)
     
  • Hang Seng

    18,430.39
    +514.84 (+2.87%)
     
  • FTSE Bursa Malaysia

    1,599.79
    -6.34 (-0.39%)
     
  • Jakarta Composite Index

    6,726.92
    -6,734.83 (-50.03%)
     
  • PSE Index

    6,366.03
    -2.77 (-0.04%)
     

Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...

On June 7, 2024, Diane Young, Senior Vice President and Chief Medical Officer of Celldex Therapeutics Inc (NASDAQ:CLDX), sold 45,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 2,115 shares of the company.

Celldex Therapeutics Inc (NASDAQ:CLDX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer and other difficult-to-treat diseases. The company's pipeline includes candidates in various stages of development, targeting specific types of cancer and other serious health conditions.

On the day of the transaction, shares of Celldex Therapeutics Inc were priced at $35.26. This pricing gives the company a market cap of approximately $2.344 billion.

ADVERTISEMENT

According to the GF Value, the intrinsic value of Celldex Therapeutics Inc is estimated at $34.72 per share, suggesting that the stock is Fairly Valued with a price-to-GF-Value ratio of 1.02.

The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on the company's past performance and estimated future business outcomes.

Over the past year, Diane Young has engaged in multiple transactions involving Celldex Therapeutics Inc shares, selling a total of 45,000 shares and purchasing none. The insider transaction history for the company shows a total of 9 insider sells and 0 insider buys over the same period.

Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex Therapeutics Inc (CLDX)
Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex Therapeutics Inc (CLDX)
Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex Therapeutics Inc (CLDX)
Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex Therapeutics Inc (CLDX)

These transactions and the current valuation metrics provide a comprehensive view of the insider activity and financial standing of Celldex Therapeutics Inc.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.